Ovarian cancer is a heterogeneous disease

被引：41

作者：

Wang, V

Li, C

Lin, M

Welch, W

Bell, D

Wong, YF

Berkowitz, R

Mok, SC

Bandera, CA ^{[1
]}

机构：

[1] Harvard Univ, Sch Med, Dana Farber Harvard Canc Ctr,Div Gynecol Oncol, Brigham & Womens Hosp,Dept Obstet Gynecol & Repro, Boston, MA 02115 USA

[2] Harvard Univ, Sch Med, Sch Publ Hlth, Boston, MA 02115 USA

[3] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA USA

[4] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA

[5] China Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China

来源：

CANCER GENETICS AND CYTOGENETICS | 2005年 / 161卷 / 02期

关键词：

D O I：

10.1016/j.cancergencyto.2004.12.014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The purpose of this study was to systematically evaluate the molecular profiles of different histologic types of epithelial ovarian cancer before the disease has metastasized beyond the ovary. Stage 1 epithelial ovarian cancers were chosen for analysis of early genetic events associated with different cell types. Allelotyping of 47 cases was performed using 224 polymorphic markers, Analysis with Fisher's exact test found markers specific for grade 3 tumors and clear cell histology. Hierarchal clustering analysis using dChip software revealed that the pattern of allele loss in eight regions on four chromosomes led to grouping of grade 3 tumors, endometrioid (grades 1 and 2) tumors, and clear cell tumors. We conclude that ovarian cancer is a heterogeneous disease in which histologic phenotypes correlate with distinct genetic patterns. (c) 2005 Elsevier Inc. All rights reserved.

引用

页码：170 / 173

页数：4

共 17 条

[1]

American Cancer Society, 2005, CANC FACTS FIG 2005

[2] Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer [J].

Bali, A ;

O'Brien, PM ;

Edwards, LS ;

Sutherland, RL ;

Hacker, NF ;

Henshall, SM .

CLINICAL CANCER RESEARCH, 2004, 10 (15) :5168-5177

[3]

BLAUSTEIN A, 2002, BLAUSTEINS PATHOLOGY

[4] CANCER STATISTICS, 1994 [J].

BORING, CC ;

SQUIRES, TS ;

TONG, T ;

MONTGOMERY, S .

CA-A CANCER JOURNAL FOR CLINICIANS, 1994, 44 (01) :7-26

[5]

CAMPBELL IG, 1998, OVARIAN CANC, V5, P159

[6] Ovca1 regulates cell proliferation, embryonic development, and tumorigenesis [J].

Chen, CM ;

Behringer, RR .

GENES & DEVELOPMENT, 2004, 18 (03) :320-332

[7] Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations [J].

Havrilesky, LJ ;

Alvarez, AA ;

Whitaker, RS ;

Marks, JR ;

Berchuck, A .

GYNECOLOGIC ONCOLOGY, 2001, 83 (03) :491-500

[8]

Hoque MO, 2003, CANCER RES, V63, P2216

[9] Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer [J].

Katsaros, D ;

Cho, W ;

Singal, R ;

Fracchioli, S ;

de la Longraisa, IAR ;

Arisio, R ;

Massobrio, M ;

Smith, M ;

Zheng, W ;

Glass, J ;

Yu, H .

GYNECOLOGIC ONCOLOGY, 2004, 94 (03) :685-692

[10] A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors [J].

Kmet, LM ;

Cook, LS ;

Magliocco, AM .

CANCER, 2003, 97 (02) :389-404

← 1 2 →